Investors are frustrated with Botox-maker Allergan — and its CEO says it’s ‘deep into the process’ of figuring out what to do next

This post was originally published on this site

Allergan said Monday during its first-quarter earnings call that it’s “deep into the process” of its strategic review of the company amid its stock price slipping over the past year.
More »